Eliquis is one of 10 drugs covered under Medicare Part D that were selected in 2024 for the first cycle of negotiation based on Total Expenditures under Part D and other criteria as required by the law. Negotiations with participating drug companies are ongoing, and any negotiated prices for th...
No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION]. Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; therefore, dosing recommend...
No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION]. Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; therefore, dosing recommend...
* All bleeding criteria included surgical site bleeding. † Includes 13 subjects with major bleeding events that occurred before the first dose of ELIQUIS (administered 12 to 24 hours post-surgery). ‡ Includes 5 subjects with major bleeding events that occurred before the first dose of ELIQUIS...
No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION]. Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; therefore, dosing recommend...
No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION]. Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; therefore, dosing recommend...
No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION]. Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; therefore, dosing recommend...
No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION]. Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; therefore, dosing recommend...
No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION]. Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; therefore, dosing recommend...
No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION]. Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; therefore, dosing recommend...